Trends in Sepsis Mortality over Time in Randomised Sepsis Trials: a Systematic Literature Review and Meta-analysis of Mortality in the Control Arm, 2002-2016

Overview

Journal Crit Care

Specialty Critical Care

Date 2019 Jul 5

PMID 31269976

Citations 56

Authors

Robert Luhr

Yang Cao

Bo Soderquist

Sara Cajander

Affiliations

Soon will be listed here.

Abstract

Background: Epidemiologic data have shown an increasing incidence and declining mortality rate in sepsis. However, confounding effects due to differences in disease classification might have contributed to these trends. To assess if a declining mortality over time could be supported by data derived from high-quality prospective studies, we performed a meta-analysis using data from randomised controlled trials (RCTs) on sepsis. The primary aim was to assess whether the mortality in sepsis trials has changed over time. The secondary aim was to investigate how many of the included trials could show efficacy of the studied intervention regarding 28-day mortality.

Methods: We searched PubMed for RCTs enrolling patients with severe sepsis and septic shock, published between 2002 and 2016. The included trials were assessed for quality and sorted by date of first inclusion. A meta-analysis was performed to synthesise data from the individual sepsis trials.

Results: Of 418 eligible articles, 44 RCTs on sepsis were included in the analysis, enrolling 13,315 patients in the usual care arm between 1991 and 2013. In this time period, mortality decreased by 0.42% annually (p = 0.04) to give a total decline of 9.24%. In subgroup analyses with adjustments for APACHE II, SAPS II and SOFA scores, the observed time trend was not significant (p = 0.45, 0.23 and 0.98 respectively). Only four of the included trials showed any efficacy with regard to mortality.

Conclusions: Data from RCTs show a declining trend in 28-day mortality in severe sepsis and septic shock patients during the years from 1991 to 2013. However, when controlling for severity at study inclusion, there was no significant change in mortality over time. The number of trials presenting new treatment options was low.

Trial Registration: PROSPERO CRD42018091100 . Registered 27 August 2018.

Citing Articles

Advancing sepsis diagnosis and immunotherapy machine learning-driven identification of stable molecular biomarkers and therapeutic targets.

Xiong W, Zhan Y, Xiao R, Liu F Sci Rep. 2025; 15(1):8333.

PMID: 40065038 PMC: 11894075. DOI: 10.1038/s41598-025-93010-8.

Exploring Core Genes Associated with Sepsis and Systemic Inflammatory Response Syndrome Using Single-Cell Sequencing Technology.

Shen Y, Leng L, Hu Y J Inflamm Res. 2025; 18:1815-1838.

PMID: 39935525 PMC: 11811729. DOI: 10.2147/JIR.S448900.

Validation of SCAI Shock Staging in Critically Ill Medical Intensive Care Unit Patients With Sepsis and Septic Shock.

Mukhtar O, Lal A, Jentzer J, Kashani K J Community Hosp Intern Med Perspect. 2025; 15(1):13-21.

PMID: 39867142 PMC: 11759074. DOI: 10.55729/2000-9666.1436.

Association between 24-hour urine volume and 28-day intensive care unit mortality in sepsis patients: a multi-center retrospective cohort study.

Lin Y, Lin W, Fu C, Sun R, Hong W, Chen X Front Med (Lausanne). 2024; 11:1486232.

PMID: 39659626 PMC: 11628257. DOI: 10.3389/fmed.2024.1486232.

SPP1 is a plasma biomarker associated with the dia gnosis and prediction of prognosis in sepsis.

Shen Y, Xiong W, Hu Y, Zhong W Sci Rep. 2024; 14(1):27205.

PMID: 39516332 PMC: 11549466. DOI: 10.1038/s41598-024-78420-4.

References

Capuzzo M, Valpondi V, Sgarbi A, Bortolazzi S, Pavoni V, Gilli G . Validation of severity scoring systems SAPS II and APACHE II in a single-center population. Intensive Care Med. 2001; 26(12):1779-85. DOI: 10.1007/s001340000715. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Thompson S, Higgins J . How should meta-regression analyses be undertaken and interpreted?. Stat Med. 2002; 21(11):1559-73. DOI: 10.1002/sim.1187. View

Levy M, Fink M, Marshall J, Abraham E, Angus D, Cook D . 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31(4):1250-6. DOI: 10.1097/01.CCM.0000050454.01978.3B. View

Abraham E, Laterre P, Garg R, Levy H, Talwar D, Trzaskoma B . Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005; 353(13):1332-41. DOI: 10.1056/NEJMoa050935. View

Kumar A, Roberts D, Wood K, Light B, Parrillo J, Sharma S . Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34(6):1589-96. DOI: 10.1097/01.CCM.0000217961.75225.E9. View

Angstwurm M, Engelmann L, Zimmermann T, Lehmann C, Spes C, Abel P . Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med. 2006; 35(1):118-26. DOI: 10.1097/01.CCM.0000251124.83436.0E. View

Levi M, Levy M, Williams M, Douglas I, Artigas A, Antonelli M . Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med. 2007; 176(5):483-90. DOI: 10.1164/rccm.200612-1803OC. View

Dhainaut J, Antonelli M, Wright P, Desachy A, Reignier J, Lavoue S . Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock. Intensive Care Med. 2009; 35(7):1187-95. DOI: 10.1007/s00134-009-1436-1. View

10.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

11.

Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo J . Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009; 136(5):1237-1248. DOI: 10.1378/chest.09-0087. View

12.

Shorr A, Janes J, Artigas A, Tenhunen J, Wyncoll D, Mercier E . Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated). Crit Care. 2010; 14(6):R229. PMC: 3219981. DOI: 10.1186/cc9382. View

13.

Ghanem-Zoubi N, Vardi M, Laor A, Weber G, Bitterman H . Assessment of disease-severity scoring systems for patients with sepsis in general internal medicine departments. Crit Care. 2011; 15(2):R95. PMC: 3219360. DOI: 10.1186/cc10102. View

14.

Ranieri V, Thompson B, Barie P, Dhainaut J, Douglas I, Finfer S . Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012; 366(22):2055-64. DOI: 10.1056/NEJMoa1202290. View

15.

Perner A, Haase N, Guttormsen A, Tenhunen J, Klemenzson G, Aneman A . Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012; 367(2):124-34. DOI: 10.1056/NEJMoa1204242. View

16.

Guntupalli K, Dean N, Morris P, Bandi V, Margolis B, Rivers E . A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit Care Med. 2013; 41(3):706-16. DOI: 10.1097/CCM.0b013e3182741551. View

17.

Annane D, Timsit J, Megarbane B, Martin C, Misset B, Mourvillier B . Recombinant human activated protein C for adults with septic shock: a randomized controlled trial. Am J Respir Crit Care Med. 2013; 187(10):1091-7. DOI: 10.1164/rccm.201211-2020OC. View

18.

Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S . Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013; 310(16):1683-91. DOI: 10.1001/jama.2013.278477. View

19.

Stevenson E, Rubenstein A, Radin G, Wiener R, Walkey A . Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis*. Crit Care Med. 2013; 42(3):625-31. PMC: 4313930. DOI: 10.1097/CCM.0000000000000026. View

20.

De Blasi R . Severe sepsis and septic shock. N Engl J Med. 2013; 369(21):2062-3. DOI: 10.1056/NEJMc1312359. View